An analysis of a ‘community-driven’ reconstruction of the human metabolic network by unknown
REVIEW ARTICLE
An analysis of a ‘community-driven’ reconstruction of the human
metabolic network
Neil Swainston • Pedro Mendes • Douglas B. Kell
Received: 16 May 2013 / Accepted: 28 June 2013 / Published online: 12 July 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Following a strategy similar to that used in
baker’s yeast (Herrga˚rd et al. Nat Biotechnol 26:1155–1160,
2008). A consensus yeast metabolic network obtained from a
community approach to systems biology (Herrga˚rd et al.
2008; Dobson et al. BMC Syst Biol 4:145, 2010). Further
developments towards a genome-scale metabolic model of
yeast (Dobson et al. 2010; Heavner et al. BMC Syst Biol
6:55, 2012). Yeast 5—an expanded reconstruction of the
Saccharomyces cerevisiae metabolic network (Heavner
et al. 2012) and in Salmonella typhimurium (Thiele et al.
BMC Syst Biol 5:8, 2011). A community effort towards a
knowledge-base and mathematical model of the human
pathogen Salmonella typhimurium LT2 (Thiele et al. 2011), a
recent paper (Thiele et al. Nat Biotechnol 31:419–425,
2013). A community-driven global reconstruction of human
metabolism (Thiele et al. 2013) described a much improved
‘community consensus’ reconstruction of the human
metabolic network, called Recon 2, and the authors (that
include the present ones) have made it freely available via a
database at http://humanmetabolism.org/ and in SBML
format at Biomodels (http://identifiers.org/biomodels.db/
MODEL1109130000). This short analysis summarises the
main findings, and suggests some approaches that will be
able to exploit the availability of this model to advantage.
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1 Main findings of the Recon 2 paper
A highly curated consensus reconstruction of the human
metabolic network, termed Recon 2, was recently released
(Thiele et al. 2013). The development of the network fol-
lowed a community ‘jamboree’ approach (Herrga˚rd et al.
2008; Dobson et al. 2010; Heavner et al. 2012; Thiele and
Palsson 2010), exploiting both genomic and literature data
to expand upon existing reconstructions (Duarte et al.
2007; Ma et al. 2007; Gille et al. 2010) to produce a ‘basal’
network that contains 7,440 reactions, 5,063 metabolite
pools and 2,626 unique metabolites. The reconstruction is
extensively semantically annotated (Kell and Mendes
2008; Courtot et al. 2011), fully compliant with the
MIRIAM standard (Le Nove`re et al. 2005), unambiguously
identifying cellular compartments, metabolites, genes and
enzymes with publicly available, external database terms
(Krause et al. 2011). Thus, cellular compartments are
annotated with Gene Ontology (GO) terms, while metabo-
lites are annotated with terms from resources such as
Chemical Entities of Biological Interest (ChEBI) (Hastings
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et al. 2013) as well as using IUPAC International Chemical
Identifier (InChI http://www.iupac.org/home/publications/e-
resources/inchi.html) terms (Coles et al. 2005) where pos-
sible. Reactions are curator-validated and annotated with
PubMed literature references, standardized GO evidence
codes, and a confidence scoring system ranging from 0 (no
evidence) to 4 (biochemical evidence). Metabolic reactions
were checked to ensure correct stoichiometry, (ir)revers-
ibility, the correct assignment of gene association and
enzyme rules, and mass and charge balancing. Appropriate
transport reactions were also included and these followed
the same level of annotation as reactions.
In contrast to existing resources such as KEGG
(Kanehisa and Goto 2000) or the Human Metabolome
Database (HMDB) (Wishart et al. 2007), Recon 2 acts as
both a knowledgebase and a predictive model, amenable to
constraint-based analysis approaches such as flux balance
analysis (Orth et al. 2010). To demonstrate this utility, the
Recon 2 authors focused on five analyses of immediate
interest. First they defined a metabolic task as a nonzero
flux through a reaction or through a pathway leading to the
production of a metabolite B from a metabolite A; 354 such
metabolic tasks were defined and all carried out success-
fully in silico. Secondly, they established whether known
mutations producing ‘inborn errors of metabolism’ (IEMs)
did have the predicted effect on biomarkers (54 reported
biomarkers for 49 different IEMs, with an accuracy of
77 %; see also Shlomi et al. 2009). Thirdly, they showed
that Recon 2 should predict a large fraction of metabolites
that are excreted (the ‘metabolic footprint’ (Allen et al.
2003) or ‘exometabolome’ (Kell et al. 2005)). Fourthly,
based on expression profiling data from the Human Protein
Atlas (Uhle´n et al. 2010), they generated 65 draft cell-type-
specific models, and fifthly they found (notwithstanding the
rather promiscuous behaviour of many drugs (Hopkins
2008, 2009; Kell et al. 2013)) that they could map 1,290
drugs to 308 enzyme and enzymatic complexes.
2 Some known shortcomings of Recon 2
While Recon 2 represents the ‘state of the art’ of public
human metabolic network reconstructions, it should be
acknowledged that it does have some known shortcomings,
including the fact that a number of known metabolites and
reactions (including those involving unliganded iron
(Hower et al. 2009; Kell 2009, 2010; Chifman et al. 2012;
Funke et al. 2013)) have still to be included, and there are
increasing numbers of ‘unexpected’ metabolite-protein
reactions that are being discovered (Li et al. 2010; Li and
Snyder 2011; Kell 2011; Kell et al. 2013). These are thus
mainly ‘false negatives’ (Broadhurst and Kell 2006), and
dealing with them is clearly one of the goals that will
remain in any continuing curation process. It is recognised
that the network reconstruction process is iterative (Reed
and Palsson 2003), and the metabolomics and systems
biology communities are encouraged to contribute to this
ongoing effort. Following an approach that has been
applied successfully in the generation of subsequent itera-
tions of the yeast consensus model (Herrga˚rd et al. 2008;
Dobson et al. 2010; Heavner et al. 2012), suggested updates
and amendments can be e-mailed to network.reconstruction
@manchester.ac.uk.
3 What the Recon 2 network will allow us
to do or to do better
3.1 General benefits of network models
As discussed previously (Kell 2006a; b), the availability of
a systems biology model of a metabolic network allows
one to effect a variety of analyses, some of which are
illustrated in Fig. 1. We here mention just a few that are
likely to be of most interest to the metabolomics
community.
3.2 Improved predictions of metabolic fluxes,
including in biotechnology
Given the topology of a network, and the stoichiometric
and thermodynamic constraints under which metabolic
networks must operate (Palsson 2006; Kell 2006a; b), it is
possible to use generalised kinetics to predict metabolic
fluxes (Liebermeister and Klipp 2006; Smallbone et al.
2007; Smallbone and Simeonidis 2008; Smallbone et al.
2010). The accuracy of these predictions can of course be
enhanced by the use of known kinetic rate equations (Li
et al. 2010), and even by expression profiles alone (Lee
et al. 2012). Such an approach has been applied, exploiting
both transcriptomics and fluxomics data, to constrain
models derived from a precursor of Recon 2 in order to
elucidate and validate new drug targets in renal-cell cancer
(Frezza et al. 2011).
The use of network biology in predicting fluxes (and
how to change them), as well as in parameter optimisation
(Mendes and Kell 1998; Moles et al. 2003; Adams et al.
2013), has enjoyed particular success in biotechnology
where it is usually the fluxes to external products that are of
interest (Park et al. 2007; Lee et al. 2012; Park et al. 2010;
Becker et al. 2011). In this area, the ongoing development
of a systems biology toolkit for Chinese Hamster Ovary
(CHO) cells, which will be increasingly utilised for bio-
technological production of pharmaceutical proteins (Kil-
degaard et al. 2013), will be aided by the development of
Recon 2, which can act as a template for development of a
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detailed metabolic reconstruction of CHO. Additionally,
one may anticipate the importance of predictions of met-
abolic fluxes in understanding nutrition and regulation in
health and disease.
3.3 Understanding and incorporating knowledge
of drugs that use known transporters
As part of the need to incorporate ‘new’ proteins and their
interactions with small molecules, one particular feature
that has become increasingly apparent in recent years is
that pharmaceutical drugs do not normally cross mem-
branes ‘passively’ through any phospholipid bilayer por-
tions that they may contain, but hitchhike on the carriers
that participate in the transmembrane transport of
intermediary metabolites (Al-Awqati 1999; Dobson and
Kell 2008; Dobson et al. 2009; Dobson et al. 2009; Kell
and Dobson 2009; Giacomini et al. 2010; Burckhardt and
Burckhardt 2011; Kell et al. 2011; Lanthaler et al. 2011;
DeGorter et al. 2012; Kell and Goodacre 2013). It is likely
that these kinds of issues contribute significantly to the
dreadful attrition rates still seen in drug development (van
der Greef and McBurney 2005; Kola and Landis 2004;
Kola 2008; Empfield and Leeson 2010; Leeson and Emp-
field 2010; Kwong et al. 2011). The availability of Recon 2
and its tissue-specific versions will now make it much
easier to correlate drug disposition with transporter
expression, and thereby determine (with suitable machine
learning analyses (Kell et al. 2001)) the roles of the dif-

































Fig. 1 A summary of some of the intellectual areas in which we can create and exploit the contents of systems biology models as encoded in
SBML
Analysis of the human metabolic network reconstruction 759
123
efflux of particular drugs. Incorporating this kind of
knowledge into subsequent iterations of Recon 2 is an
urgent priority.
3.4 Other approaches to mining the metabolic network
An important recognition (Herrga˚rd et al. 2008), continued
in Recon 2, was that of the utility of the methods of chem-
informatics (Gasteiger 2003) in providing chemically accu-
rate and database-independent descriptions of the structures
of metabolites that allowed models (such as those encoded in
SBML (Hucka et al. 2003; Hucka et al. 2004)) to be inter-
rogated computationally. In a similar vein, there is an
increasing trend towards automated reasoning about the
content of scientific papers from a systems biology point of
view (Hakenberg et al. 2004; King et al. 2005; Ananiadou
et al. 2006; Kell and Mendes 2008; Ananiadou et al. 2010;
Ray et al. 2010; Miwa et al. 2012, 2013), including about
their metabolomes (Knox et al. 2007; Attwood et al. 2009;
Attwood et al. 2010; Nobata et al. 2011; Zhou et al. 2012;
Hastings et al. 2013). The availability of Recon 2 will allow
one to ask questions such as, ‘‘how many metabolites with a
given substructure are present in the network?’’ or ‘‘which
metabolites are common (or different) between these two
networks?’’ or to plot out the distributions of various kinds of
properties that may be of interest (Dobson et al. 2009); one
such plot, simply showing the distribution of molecular
masses, is given in Fig. 2.
3.5 Comparison with the experimental metabolome
Analysis of the metabolome as encoded in biochemical
networks also leads one to recognise the importance of
comparing systems biology models with the experimental
metabolome (i.e. the concentrations of small molecules)
measured in different circumstances (‘comparative meta-
bolomics’, Raamsdonk et al. 2001; Levandi et al. 2008).
As with Recon 2, the experimental metabolome of, for
example, human serum consists of several thousands of
reproducibly detectable metabolites (O’Hagan et al. 2005;
2007; Begley et al. 2009; Zelena et al. 2009). While some
of these experimentally observed metabolites will certainly
originate from nutrients or the gut microbiome (Goodacre
2007; Li et al. 2008; Wikoff et al. 2009; Zhao and Shen
2010; Wang et al. 2011; Bennett et al. 2013; Collino et al.
2013; Heinken et al. 2013), Recon 2 allows one to set down
those that are at least encoded in the human genome
sequence, and compare these with the contents of the
various metabolome databases (Brown et al. 2009; Kamp
et al. 2012; van Ravenzwaay et al. 2012; Sawada et al.
2012; Steinbeck et al. 2012; Tautenhahn et al. 2012;
Wishart 2012; Zhou et al. 2012; Guo et al. 2013; Hastings
et al. 2013; Haug et al. 2013; Li et al. 2013; Salek et al.
2013; Sakurai et al. 2013; Wishart et al. 2013). Data
standards such as SBRML (Dada et al. 2010) allow a
straightforward comparison of network models with
experimental data encoded in a compatible format.
3.6 The importance of semantic annotation
Many of the application areas described above are depen-
dent upon the semantic awareness of Recon 2, and the
incorporation of thousands of unique, persistent, unam-
biguous semantic annotations that allow for software-dri-
ven analyses of the knowledgebase and derived models. By
representing both the network and its semantic information
using community-driven standards such as SBML (Hucka
Fig. 2 An assessment of the
distribution of molecular masses
of the metabolites in Recon 2
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et al. 2003, 2004) and MIRIAM (Le Nove`re et al. 2005),
software producers are able to develop against a given
standard, decoupling the network model from the tech-
niques used in its various more specialized analyses.
There is increasing community interest in the develop-
ment of tissue- and condition-specific models, and this task
is dependent upon the integration of large-scale ‘omics
data. Methods to perform such integration are many-fold
and are in constant development (Mo et al. 2009; Jerby
et al. 2010; Wang et al. 2012), but all are reliant on auto-
mated approaches, given that the size of the datasets
involved renders manual integration impossible. Recon 2 is
annotated with third-party identifiers across numerous
scales, from genomics through to transcriptomics, proteo-
mics and metabolomics, all of which can be mapped to
appropriate web services, allowing for their automated
interpretation (Swainston and Mendes 2009) and integra-
tion of multi-omics data (Li et al. 2008, 2008; Hyduke et al.
2013). Additionally, the definition of metabolites in struc-
tural terms permits the exploitation of cheminformatics
tools such as the Chemistry Development Toolkit
(Steinbeck et al. 2003) and Open Babel that allow one to
translate the various encodings or mappings of chemical
structures (O’Boyle et al. 2011).
Furthermore, the specification of metabolites, enzymes
and reactions in unambiguous terms facilitates the devel-
opment of knowledgebases and models of related organ-
isms, through automated or semi-automated means (Henry
et al. 2010; Swainston et al. 2011; Agren et al. 2013).
Recon 2 can therefore act as a template for the develop-
ment of metabolic reconstructions of related model
organisms, facilitating comparative studies and simulation
of metabolism between human and other model systems
(Sigurdsson et al. 2010).
4 Concluding remarks
The availability of Recon 2 allows a great many compu-
tational analyses to be performed. We have purposely
rehearsed these at a rather general level, since particular
analyses, that might be relevant to particular diseases, for
instance, are simply implementations of the more general
approaches. One new approach that will depend on the
existence of such a network as a necessary resource is
personalised medicine (Hood and Flores 2012). There one
will develop models of metabolism calibrated for each
specific individual, in large part using metabolomics
methods, to be used as bases for diagnostics and decisions
on course of treatment. Recon 2 is a very significant step
towards such a map, where such measurements have to be
anchored for various types of modelling that will underpin
personalised treatment decisions.
The development of tissue- and condition-specific
models has been demonstrated with Recon 2 and its pre-
decessors (Jerby et al. 2010; Frezza et al. 2011; Wang et al.
2012). As subsequent iterations of Recon 2 develop, it is
hoped that the scope of the knowledgebase, and the pre-
dictive power of derived models, will increase to keep pace
with advancements in the community knowledge of human
metabolism, many of which will be driven by the discipline
of metabolomics.
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